GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Net Intangibles Purchase And Sale

Hansoh Pharmaceutical Group Co (HKSE:03692) Net Intangibles Purchase And Sale : HK$-156 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Hansoh Pharmaceutical Group Co's net Intangibles purchase and sale for the six months ended in Dec. 2023 was HK$-45 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-156 Mil.

Hansoh Pharmaceutical Group Co Net Intangibles Purchase And Sale Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Net Intangibles Purchase And Sale Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial -5.36 -13.76 -18.56 -21.22 -156.33

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.13 -19.55 -2.59 -111.60 -44.73

Hansoh Pharmaceutical Group Co Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-156 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
HKSE:00867 HKSE:03320 HKSE:00570 HKSE:02096 HKSE:00512 HKSE:03933 HKSE:06185 HKSE:02005 HKSE:03613 HKSE:01349 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ NSE:DIVISLAB
Traded in Other Exchanges
3KY:Germany
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Website
https://www.hspharm.com
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines